ProMetic Life Sciences Inc. (PLI) 2003年年度报告「TSX」.pdf

1、FOCUSON REAL VALUE2003ANNUALREPORTCOMPANY PROFILEENABLING A WORLD OF BETTER HEALTH FOR ALLProMetic Life Sciences Inc.is a leading international biopharmaceutical company specializing in research,development,manufacture and commercialization of products and applications for the biopharmaceutical indu

2、stry.Its proprietaryplatform technologies are essential to the manufacture and development of therapeutics,the elimination of pathogens,proteomics,diagnostics and large-scale drug purification.ProMetic is currently focused on two main goals:the first being to use its Mimetic Ligands core technology

3、to enablefurther improvements to well-established therapies and create better and more efficient technologies for new drugs anddisease treatments.The second focus consists of further leveraging its expertise in protein therapeutics and medicinalchemistry,by developing proprietary value-added drugs a

4、nd therapies in the fields of cancer,inflammatory/auto-immuneand infectious diseases.In doing so,ProMetic will enhance the lives of people living in developed and developingcountries around the world,while at the same time creating ethical financial opportunities for its shareholders.ProMetic is in

5、a unique position in that it has a large number of diverse partnerships with some key companies in theglobal biotechnology and pharmaceutical industries and therefore,can potentially generate revenues from a numberof diverse sources.These include the sale of proprietary therapeutics,pathogen removal

6、 devices and bioseparationmedia,as well as royalties and milestone payments from products sold by partners who use ProMetics proprietarytechnology in their manufacturing processes.Clinical development and marketing risks are shared throughpartnerships with multinational companies.Founded in 1994,Pro